James McMahon – Kerrang! Editor from 2011 to 2017 – has died from soft tissue sarcoma.

Immutep (IMMP) has released an update. Immutep Limited has announced promising results from its Phase II trial of eftilagimod alpha, combined ...

Tributes are being paid to former Kerrang! editor, music journalist and podcaster James McMahon, who passed away aged 44 on ...

Adaptimmune’s Phase II IGNYTE-ESO trial investigating experimental T cell therapy lete-cel has achieved its primary endpoint.

First patient dosed in randomized, Phase 2 study in presurgical triple negative breast cancer SHELTON, Conn., Nov. 13, 2024 /PRNewswire/ -- Intensity Therapeutics ...

Efti + KEYTRUDA combo shows strong efficacy for NSCLC patients in Immutep's phase 1 study. Read why IMMP stock may see upside ...

Adaptimmune Therapeutics’ lete-cel data achieves primary endpoint in pivotal phase 2 IGNYTE-ESO trial: Philadelphia Friday, November 15, 2024, 13:00 Hrs [IST] Adaptimmune Therap ...

Equities researchers at StockNews.com began coverage on shares of TRACON Pharmaceuticals (NASDAQ:TCON – Get Free Report) in a report released on Wednesday. The firm set a “hold” rating on the ...

Reese McHenry was often described as a force of nature. After growing up in northern Minnesota and western Wisconsin, she ...

Just as the fledgling establishment carved its niche in the community, it was forced to shutter when Fraser was diagnosed ...